[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641850":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":11,"studyPopulation":11,"armGroups":29,"interventions":36,"overallOfficials":41,"centralContacts":45,"locations":54,"responsibleParty":215,"collaborators":11,"id":217,"slug":218,"hasResults":219,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":11,"eligibilityCriteria":223,"healthyVolunteers":219,"sex":224,"minAge":225,"maxAge":226,"enrollmentInfo":227,"targetDuration":11,"studyType":230,"phases":231,"briefSummary":233,"conditions":234,"keywords":236,"overallStatus":134,"whyStopped":11,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":249},{"fullName":5,"class":6},"Eli Lilly and Company","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Change from Baseline in Cerebrospinal Fluid (CSF) Neurofilament Light Chain (NfL)",null,"Baseline through end of the Follow-up Period (Week 24)",[14,16,18,20],{"measure":15,"description":11,"timeFrame":12},"Change from Baseline in Phospho-Tau (pTau)",{"measure":17,"description":11,"timeFrame":12},"Change from Baseline in Plasma NfL",{"measure":19,"description":11,"timeFrame":12},"Pharmacokinetics (PK) Maximum LY3439539 Serum Concentration (Cmax)",{"measure":21,"description":11,"timeFrame":22},"PK: Minimum LY3439539 Serum Concentration (Cmin)","Time Frame: Baseline through end of Follow up Period (Week 24)",{"allocation":24,"interventionModel":25,"interventionModelDescription":11,"primaryPurpose":26,"observationalModel":11,"timePerspective":11,"maskingInfo":27},"NA","SINGLE_GROUP","BASIC_SCIENCE",{"masking":28,"maskingDescription":11,"whoMasked":11},"NONE",[30],{"label":31,"type":32,"description":33,"interventionNames":34},"LY3439539","EXPERIMENTAL","LY3439539 administered intravenously (IV)",[35],"Drug: LY3439539",[37],{"type":38,"name":31,"description":39,"armGroupLabels":40,"otherNames":11},"DRUG","Administered IV",[31],[42],{"name":43,"affiliation":5,"role":44},"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC\u002FGMT - 5 hours, EST)","STUDY_DIRECTOR",[46,51],{"name":47,"role":48,"phone":49,"phoneExt":11,"email":50},"Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or","CONTACT","1-317-615-4559","LillyTrials@Lilly.com",{"name":52,"role":48,"phone":11,"phoneExt":11,"email":53},"Physicians interested in becoming principal investigators please contact","clinical_inquiry_hub@lilly.com",[55,75,89,101,116,132,147,161,170,184,200],{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"Irvine Clinical Research","NOT_YET_RECRUITING","Irvine","California","92614","United States","US",{"type":64,"coordinates":65},"Point",[66,67],-117.82311,33.66946,{"lat":67,"lon":66},[70,72],{"name":11,"role":48,"phone":71,"phoneExt":11,"email":11},"949-753-1663",{"name":73,"role":74,"phone":11,"phoneExt":11,"email":11},"Elly Lee","PRINCIPAL_INVESTIGATOR",{"facility":76,"status":57,"city":77,"state":59,"zip":78,"country":61,"countryCode":62,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Healthy Brain Clinic","Long Beach","90804",{"type":64,"coordinates":80},[81,82],-118.18923,33.76696,{"lat":82,"lon":81},[85,87],{"name":11,"role":48,"phone":86,"phoneExt":11,"email":11},"562-606-5999",{"name":88,"role":74,"phone":11,"phoneExt":11,"email":11},"Dung Trinh",{"facility":90,"status":57,"city":91,"state":59,"zip":92,"country":61,"countryCode":62,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Inglewood Clinical","Los Angeles","90056",{"type":64,"coordinates":94},[95,96],-118.24368,34.05223,{"lat":96,"lon":95},[99],{"name":100,"role":74,"phone":11,"phoneExt":11,"email":11},"Maricor Grio",{"facility":102,"status":57,"city":103,"state":104,"zip":105,"country":61,"countryCode":62,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Charter Research","Orlando","Florida","32803",{"type":64,"coordinates":107},[108,109],-81.37924,28.53834,{"lat":109,"lon":108},[112,114],{"name":11,"role":48,"phone":113,"phoneExt":11,"email":11},"407-337-1000",{"name":115,"role":74,"phone":11,"phoneExt":11,"email":11},"Diana Balsalobre",{"facility":117,"status":57,"city":118,"state":11,"zip":119,"country":120,"countryCode":121,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Flinders Medical Centre","Adelaide","5042","Australia","AU",{"type":64,"coordinates":123},[124,125],138.59863,-34.92866,{"lat":125,"lon":124},[128,130],{"name":11,"role":48,"phone":129,"phoneExt":11,"email":11},"+61 482 130 622",{"name":131,"role":74,"phone":11,"phoneExt":11,"email":11},"Lauren Priest",{"facility":133,"status":134,"city":135,"state":11,"zip":136,"country":120,"countryCode":121,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"Austin Health - Heidelberg Repatriation Hospital","RECRUITING","Ivanhoe","3079",{"type":64,"coordinates":138},[139,140],145.04308,-37.76903,{"lat":140,"lon":139},[143,145],{"name":11,"role":48,"phone":144,"phoneExt":11,"email":11},"+613 9496 2388",{"name":146,"role":74,"phone":11,"phoneExt":11,"email":11},"Paul Yates",{"facility":148,"status":134,"city":149,"state":11,"zip":150,"country":120,"countryCode":121,"cosmosGeoPoint":151,"geoPoint":155,"contacts":156},"Southern Neurology","Kogarah","2217",{"type":64,"coordinates":152},[153,154],151.13564,-33.9681,{"lat":154,"lon":153},[157,159],{"name":11,"role":48,"phone":158,"phoneExt":11,"email":11},"+612 8566 1500",{"name":160,"role":74,"phone":11,"phoneExt":11,"email":11},"Raymond Schwartz",{"facility":162,"status":134,"city":163,"state":11,"zip":164,"country":120,"countryCode":121,"cosmosGeoPoint":11,"geoPoint":11,"contacts":165},"Macquarie University Hospital","Macquarie University","2109",[166,168],{"name":11,"role":48,"phone":167,"phoneExt":11,"email":11},"0298122956",{"name":169,"role":74,"phone":11,"phoneExt":11,"email":11},"James Burrell",{"facility":171,"status":134,"city":172,"state":11,"zip":173,"country":120,"countryCode":121,"cosmosGeoPoint":174,"geoPoint":178,"contacts":179},"The Alfred","Melbourne","3004",{"type":64,"coordinates":175},[176,177],144.96332,-37.814,{"lat":177,"lon":176},[180,182],{"name":11,"role":48,"phone":181,"phoneExt":11,"email":11},"0437 498 365",{"name":183,"role":74,"phone":11,"phoneExt":11,"email":11},"David Darby",{"facility":185,"status":57,"city":186,"state":11,"zip":187,"country":188,"countryCode":189,"cosmosGeoPoint":190,"geoPoint":194,"contacts":195},"Christchurch Neurology Trials","Christchurch","8011","New Zealand","NZ",{"type":64,"coordinates":191},[192,193],172.63333,-43.53333,{"lat":193,"lon":192},[196,198],{"name":11,"role":48,"phone":197,"phoneExt":11,"email":11},"+ 64 33786662",{"name":199,"role":74,"phone":11,"phoneExt":11,"email":11},"Timothy Anderson",{"facility":201,"status":134,"city":202,"state":11,"zip":203,"country":202,"countryCode":204,"cosmosGeoPoint":205,"geoPoint":209,"contacts":210},"Lilly Centre for Clinical Pharmacology","Singapore","138623","SG",{"type":64,"coordinates":206},[207,208],103.85007,1.28967,{"lat":208,"lon":207},[211,213],{"name":11,"role":48,"phone":212,"phoneExt":11,"email":11},"+65 6413 9811",{"name":214,"role":74,"phone":11,"phoneExt":11,"email":11},"Jeffer Hann Wei Pang",{"type":216,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100641850","phase-1-a-study-of-ly3439539-in-participants-with-alzheimers-disease-100641850",false,"NCT07598370","A Study of LY3439539 in Participants With Alzheimer's Disease","A Phase 1, Open Label, Multiple-Dose Study to Assess the Changes in Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Following Treatment With LY3439539 in Participants With Symptomatic Alzheimer's Disease","Inclusion Criteria:\n\n* Have gradual and progressive change in memory function reported by the participant or informant for 6 months or longer consistent with a diagnosis of dementia due to Alzheimer's disease\n* Have a Mini Mental Score Examination score of 16 to 24, inclusive\n* Meet plasma pTau criteria, as defined by the sponsor\n* Have body mass index within the range of 17 and 32 kilograms per square meter (kg\u002Fm²) (inclusive) at screening\n* Are women not of childbearing potential and men willing to practice effective contraception throughout the study.\n* Have adequate premorbid literacy, vision, and hearing throughout the study duration and able to complete study procedures.\n* Have at least 1, and up to 2, study partners who are in frequent contact with the participant (defined as at least 10 hours per week).\n\nExclusion Criteria:\n\n* Have any contraindications for magnetic resonance imaging (MRI), including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants\u002Fcardiac pacemaker.\n* Have a screening MRI that shows evidence of significant abnormality.\n* Have history of suicidal behavior, or a lifetime history of suicide attempt or acute suicidality.\n* Have a history of\n\n  * Severe or ongoing allergy or hypersensitivity reactions\n  * Hypersensitivity to immunizations or immunoglobulins\n  * Two or more clinically significant or severe drug allergies,\n  * Intolerance to topical corticosteroids or severe posttreatment hypersensitivity reactions\n* Have current serious or unstable illnesses, including hepatic, renal, gastroenterological, respiratory, cardiovascular, neurologic (other than AD), psychiatric, endocrinologic, immunologic, hematologic disease, or other conditions\n* Require treatment with another monoclonal antibody or have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing.\n* Have criteria that would preclude a lumbar puncture (LP).\n* Are currently enrolled in a clinical study involving an investigational product (IP) or any other type of medical research judged not to be scientifically or medically compatible with this study.\n* Have a current exposure to amyloid-targeting therapies (ATTs). Prior exposure to ATTs greater than 1 year from the last dose may be permitted at the discretion of the investigator and in consultation with the sponsor.","ALL","50 Years","85 Years",{"count":228,"type":229},30,"ESTIMATED","INTERVENTIONAL",[232],"PHASE1","The purpose of this study is to see how LY3439539 affects certain proteins found in the spinal fluid of participants with Alzheimer's disease.\n\nParticipation in the study will last approximately 9 months with visits about once a month.",[235],"Alzheimer Disease",[237,238,239],"Cognitive Impairment","Neurodegenerative Diseases","Dementia","2026-09-03",{"date":242,"type":243},"2026-09-04","ACTUAL",{"date":245,"type":243},"2026-05-21",{"date":247,"type":229},"2027-08",{"name":5,"class":6},11]